Trade Summary

3 days ago, Viehbacher Christopher, serving as Dir at Braveheart Bio, Inc. (BRVE), purchased 83,333 shares at $18.00 per share, for a total transaction value of $1,499,994.00. Following this transaction, Viehbacher Christopher now holds 609,519 shares of BRVE.

This purchase represents a 15.84% increase in Viehbacher Christopher's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, August 7, 2026 and publicly disclosed via SEC Form 4 filing on Friday, August 7, 2026 at 4:31 PM ET, meaning the disclosure happened on the same day as the trade.

Braveheart Bio, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.